首页> 美国卫生研究院文献>Cancer Science >Mitochondrial network structure homeostasis and cell death
【2h】

Mitochondrial network structure homeostasis and cell death

机译:线粒体网络结构稳态与细胞死亡

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mitochondria are the major cellular energy‐producing organelles and intracellular source of reactive oxygen species. These organelles are responsible for driving cell life and death through mitochondrial network structure homeostasis, which is determined by a balance of fission and fusion. Recent advances revealed that a number of components of the fission and fusion machinery, including dynamin‐related protein 1 (Drp1), mitofusin1/2 (Mfn1/2) and Optic atrophy 1 (OPA1), that have been implicated in mitochondrial shape changes are indispensible for autophagy, apoptosis and necroptosis. Drp1 is the main regulator of mitochondrial fission and has become a key point of contention. The controversy focuses on whether Drp1 is directly involved in the regulation of cell death and, if involved, whether is it a stimulator or a negative regulator of cell death. Here, we examine the relevance of the homeostasis of the mitochondrial network structure in 3 different types of cell death, including autophagy, apoptosis and necroptosis. Furthermore, a variety of cancers often exhibit a fragmented mitochondrial phenotype. Thus, the fragmented ratio can reflect tumor progression that predicts prognosis and therapeutic response. In addition, we investigate whether the targeting of the mitochondrial fission protein Drp1 could be a novel therapeutic approach.
机译:线粒体是主要的细胞能量产生细胞器和细胞内活性氧的来源。这些细胞器负责通过线粒体网络结构稳态来驱动细胞的生命和死亡,线粒体网络结构的稳态取决于裂变和融合的平衡。最近的进展表明,裂变和融合机制的许多成分包括与线粒体形状变化有关的动力相关蛋白1(Drp1),mitofusin1 / 2(Mfn1 / 2)和视神经萎缩1(OPA1)。自噬,细胞凋亡和坏死病必不可少。 Drp1是线粒体裂变的主要调节剂,已成为争论的重点。争议的焦点是Drp1是否直接参与细胞死亡的调控,如果涉及,是否是细胞死亡的刺激剂或负调控剂。在这里,我们检查线粒体网络结构的稳态在3种不同类型的细胞死亡中的相关性,包括自噬,细胞凋亡和坏死病。此外,多种癌症通常表现出线粒体表型断裂。因此,碎裂的比率可以反映预测预后和治疗反应的肿瘤进展。此外,我们调查线粒体裂变蛋白Drp1的靶向是否可能是一种新颖的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号